{"filing":{"accession_number":"0001104659-26-116720","cik":"0001094038","ticker":"MRKR","company_name":"Marker Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"tm2627740d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926116720/tm2627740d1_8k.htm"},"events":[{"id":35936,"run_id":33124,"accession_number":"0001104659-26-116720","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Marker Therapeutics announced receipt of a $2.6 million FDA Orphan Products Development Grant to advance its lead investigational MAR-T cell therapy, MT-601, in pancreatic cancer. This is a material operational and strategic milestone—non-dilutive funding from a highly competitive federal program that validates the scientific rationale of the company's platform and supports clinical development. While not fitting a specific named event type, this clearly represents a material operational/strategic achievement that would affect a reasonable investor's assessment of the company's development trajectory and funding position.","company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40171,"accession_number":"0001104659-26-116720","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Marker Therapeutics announced receipt of a $2.6 million FDA Orphan Products Development Grant to advance its lead investigational MAR-T cell therapy, MT-601, in pancreatic cancer. This is a material operational and strategic milestone—non-dilutive funding from a highly competitive federal program that validates the scientific rationale of the company's platform and supports clinical development. While not fitting a specific named event type, this clearly represents a material operational/strategic achievement that would affect a reasonable investor's assessment of the company's development trajectory and funding position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:13:40.563496+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40171,"accession_number":"0001104659-26-116720","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Marker Therapeutics announced receipt of a $2.6 million FDA Orphan Products Development Grant to advance its lead investigational MAR-T cell therapy, MT-601, in pancreatic cancer. This is a material operational and strategic milestone—non-dilutive funding from a highly competitive federal program that validates the scientific rationale of the company's platform and supports clinical development. While not fitting a specific named event type, this clearly represents a material operational/strategic achievement that would affect a reasonable investor's assessment of the company's development trajectory and funding position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:13:40.563496+00:00","company_name":"Marker Therapeutics, Inc.","ticker":"MRKR","filing_date":"2026-10-19"}]}